Rapid testing versus karyotyping in Down's syndrome screening: Cost-effectiveness and detection of clinically significant chromosome abnormalities

European Journal of Human Genetics

Volumn 19, Issue 1, 2011, Pages 3-9

  Gekas, Jean ^a,b   Van Den Berg, David Gradus ^c   Durand, Audrey ^a   Vallée, Maud ^b   Wildschut, Hajo Izaäk Johannes ^c   Bujold, Emmanuel ^a   Forest, Jean Claude ^b   Rousseau, François ^b   Reinharz, Daniel ^a  

^a UNIVERSITÉ LAVAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CHROMOSOME ABERRATION; CHROMOSOME MOSAICISM; COMPARATIVE STUDY; COMPUTER SIMULATION; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC PROCEDURE; DOWN SYNDROME; EDWARDS SYNDROME; FEMALE; FETUS KARYOTYPING; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; INTERMETHOD COMPARISON; KARYOTYPE 45,X; KARYOTYPE 47,XXX; KARYOTYPE 47,XXY; KARYOTYPE 47,XYY; MARKER CHROMOSOME; PATAU SYNDROME; POLYMERASE CHAIN REACTION; PREGNANCY OUTCOME; PRENATAL SCREENING; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; RAPID ANEUPLOIDY DIAGNOSIS; ROBERTSONIAN CHROMOSOME TRANSLOCATION; SEX CHROMOSOME MOSAICISM; STRUCTURAL CHROMOSOME ABERRATION; TETRAPLOIDY; TRIPLOIDY; UNITED KINGDOM;

EID: 78650068383     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/ejhg.2010.138     Document Type: Article

References (49)

1. Caine A, Maltby AE, Parkin CA, Waters JJ, Crolla JA: Prenatal detection of Down's syndrome by rapid aneuploidy testing for chromosomes 13, 18, and 21 by FISH or PCR without a full karyotype: a cytogenetic risk assessment. Lancet 2005; 366: 123-128.
2. Wald NJ, Hackshaw AK, Watt H: Nuchal translucency and trisomy 18. Prenat Diagn 1999; 19: 995-996.
3. Wapner R, Thom E, Simpson JL et al: First-trimester screening for trisomies 21 and 18. N Engl J Med 2003; 349: 1405-1413.
4. NEQAS: National External Quality Assessment Scheme in clinical cytogenetics. Annu Rep 2000.
5. Boyd PA, Devigan C, Khoshnood B, Loane M, Garne E, Dolk H: Survey of prenatal screening policies in Europe for structural malformations and chromosome anomalies, and their impact on detection and termination rates for neural tube defects and Down's syndrome. BJOG 2008; 115: 689-696.
6. NSC: Fetal Anomaly Screening Programme - Screening for Down's Syndrome: UK NSC Policy recommendations 2007-2010: Model of Best Practice. UK: Department of Health, 2008.
7. ACOG Committee on Practice Bulletins: ACOG Practice Bulletin No 77: screening for fetal chromosomal abnormalities. Obstet Gynecol 2007; 109: 217-227.
8. Summers AM, Langlois S, Wyatt P, Wilson RD: Prenatal screening for fetal aneuploidy. J Obstet Gynaecol Can 2007; 29: 146-179.
9. Waters JJ, Waters KS: Trends in cytogenetic prenatal diagnosis in the UK: results from UKNEQAS external audit, 1987-1998. Prenat Diagn 1999; 19: 1023-1026.
10. Cirigliano V, Voglino G, Canadas MP et al: Rapid prenatal diagnosis of common chromosome aneuploidies by QF-PCR. Assessment on 18,000 consecutive clinical samples. Mol Hum Reprod 2004; 10: 839-846.
11. Hulten MA, Dhanjal S, Pertl B: Rapid and simple prenatal diagnosis of common chromosome disorders: advantages and disadvantages of the molecular methods FISH and QF-PCR. Reproduction 2003; 126: 279-297.
12. Mann K, Donaghue C, Fox SP, Docherty Z, Ogilvie CM: Strategies for the rapid prenatal diagnosis of chromosome aneuploidy. Eur J Hum Genet 2004; 12: 907-915.
13. Verma L, Macdonald F, Leedham P, McConachie M, Dhanjal S, Hulten M: Rapid and simple prenatal DNA diagnosis of Down's syndrome. Lancet 1998; 352: 9-12.
14. Shaffer LG, Bui TH: Molecular cytogenetic and rapid aneuploidy detection methods in prenatal diagnosis. Am J Med Genet C Semin Med Genet 2007; 145C: 87-98.
15. Grimshaw GM, Szczepura A, Hulten M et al: Evaluation of molecular tests for prenatal diagnosis of chromosome abnormalities. Health Technol Assess 2003; 7: 1-146.
16. Evans MI, Henry GP, Miller WA et al: International, collaborative assessment of 146,000 prenatal karyotypes: expected limitations if only chromosome-specific probes and fluorescent in-situ hybridization are used. Hum Reprod 1999; 14: 1213-1216.
17. Mann K, Fox SP, Abbs SJ et al: Development and implementation of a new rapid aneuploidy diagnostic service within the UK National Health Service and implications for the future of prenatal diagnosis. Lancet 2001; 358: 1057-1061.
18. Boormans EM, Birnie E, Bilardo CM, Oepkes D, Bonsel GJ, Van Lith JM: Karyotyping or rapid aneuploidy detection in prenatal diagnosis- The different views of users and providers of prenatal care. BJOG 2009; 116: 1396-1399.
19. UK Department of Health: Our Inheritance, Our Future: Realising the Potential of Genetics in the NHS. London: Stationery Office, 2003.
20. Test and Technology Transfer Committee: Technical and clinical assessment of fluorescence in situ hybridization: an ACMG/ASHG position statement. I. Technical considerations. Genet Med 2000; 2: 356-361.
21. Thein AT, Abdel-Fattah SA, Kyle PM, Soothill PW: An assessment of the use of interphase FISH with chromosome specific probes as an alternative to cytogenetics in prenatal diagnosis. Prenat Diagn 2000; 20: 275-280.
22. Thilaganathan B, Sairam S, Ballard T, Peterson C, Meredith R: Effectiveness of prenatal chromosomal analysis using multicolor fluorescent in situ hybridisation. BJOG 2000; 107: 262-266.
23. Wald NJ, Rudnicka AR, Bestwick JP: Sequential and contingent prenatal screening for Down syndrome. Prenat Diagn 2006; 26: 769-777.
24. Caughey AB: Cost-effectiveness analysis of prenatal diagnosis: methodological issues and concerns. Gynecol Obstet Invest 2005; 60: 11-18.
25. Gekas J, Gagne G, Bujold E et al: Comparison of different strategies in prenatal screening for Down's syndrome: cost effectiveness analysis of computer simulation. BMJ 2009; 338: b138.
26. Wald NJ, RodeckC, Hackshaw AK, Walters J, Chitty L, Mackinson AM: First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). J Med Screen 2003; 10: 56-104.
27. Morris JK, Wald NJ, Watt HC: Fetal loss in Down syndrome pregnancies. Prenat Diagn 1999; 19: 142-145.
28. Snijders R: Fetal loss in Down syndrome pregnancies. Prenat Diagn 1999; 19: 1180.
29. Spencer K: What is the true fetal loss rate in pregnancies affected by trisomy 21 and how does this influence whether first trimester detection rates are superior to those in the second trimester? Prenat Diagn 2001; 21: 788-789.
30. Wald N Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM, Bestwick JP: Correction to SURUSS report. J Med Screen 2006; 13: 51-52.
31. Malone FD, Canick JA, Ball RH et al: First-trimester or second-trimester screening, or both, for Down's syndrome. N Engl J Med2005; 353: 2001-2011.
32. Leung WC, Lam YH, Wong Y, Lau ET, Tang MH: The effect of fast reporting by amnio-PCR on anxiety levels in women with positive biochemical screening for Down syndrome-a randomized controlled trial. Prenat Diagn 2002; 22: 256-259.
33. Chitty LS, Kagan KO, Molina FS, Waters JJ, Nicolaides KH: Fetal nuchal translucency scan and early prenatal diagnosis of chromosomal abnormalities by rapid aneuploidy screening: observational study. BMJ 2006; 332: 452-455.
34. Buckley F, Buckley SJ: Costs of prenatal genetic screening. Lancet 2008; 372: 1789-1791.
35. Wald N, RodeckC, Rudnicka A, Hackshaw A: Nuchal translucency and gestational age. Prenat Diagn 2004; 24: 150-151.
36. Nicolaides KH, Spencer K, Avgidou K, Faiola S, Falcon O: Multicenter study of firsttrimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk-orientated twostage first-trimester screening. Ultrasound Obstet Gynecol 2005; 25: 221-226.
37. Sundberg K, Bang J, Smidt-Jensen S et al: Randomised study of risk of fetal loss related to early amniocentesis versus chorionic villus sampling. Lancet 1997; 350: 697-703.
38. Jacobs PA, Browne C, Gregson N, Joyce C, White H: Estimates of the frequency of chromosome abnormalities detectable in unselected newborns using moderate levels of banding. J Med Genet 1992; 29: 103-108.
39. Knight SJ, Regan R, Nicod A et al: Subtle chromosomal rearrangements in children with unexplained mental retardation. Lancet 1999; 354: 1676-1681.
40. Miller DT, Adam MP, AradhyaS etal: Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet 2010; 86: 749-764.
41. Seror V: Fitting observed and theoretical choices - women's choices about prenatal diagnosis of Down syndrome. Health Econ 2008; 17: 557-577.
42. Wald NJ, Watt HC, Hackshaw AK: Integrated screening for Down's syndrome on the basis of tests performed during the first and second trimesters. N Engl J Med 1999; 341: 461-467.
43. Faucher E, Bujold E, Brassard N, Himaya E, Gekas J: FISH analysis for fetal karyotype : what are the factors associated with its failure? Prenat Diagn 2008; 28: S27.
44. Bestwick JP, Wald N, Rudnicka AR: Cost of integrated, sequential and contingent prenatal screening for Down's syndrome. BMJ 2009; e-pub ahead of print 2 April 2009.
45. Midtrimester amniocentesis for prenatal diagnosis: Safety and accuracy. JAMA 1976; 236:1471-1476.
46. Alfirevic Z, Sundberg K, Brigham S: Amniocentesis and chorionic villus sampling for prenatal diagnosis. Cochrane Database Syst Rev2003; (3): CD003252.
47. Mujezinovic F, Alfirevic Z: Procedure-related complications of amniocentesis and chorionic villous sampling: a systematic review. Obstet Gynecol 2007; 110: 687-694.
48. Tabor A, Alfirevic Z: Update on procedure-related risks for prenatal diagnosis techniques. Fetal Diagn Ther 2009; 27: 1-7.
49. Tabor A, Vestergaard CH, Lidegaard O: Fetal loss rate after chorionic villus sampling and amniocentesis: an 11-year national registry study. Ultrasound Obstet Gynecol 2009; 34: 19-24.